Moreover, a recent study has reported that CMTM5-v1, an alternative splicing protein isoform of CMTM5, may promote the response sensitivity of prostate cancer cells to Gefitinib, a tyrosine kinase inhibitor targeting the EGFR56. This evidence concerns the gene CMTM5 and prostate carcinoma.